Nasdaq:TOI
Oncology Institute, Inc.
A clinical-stage oncology company generating substantial revenue but facing negative net income due to high R&D and administrative costs.
Key Metrics
Investment Thesis
Bull Case
Investors may view TOI as a high-potential turnaround story given its impressive 54% revenue growth trajectory and strong balance sheet liquidity with ending cash at $49.7M. The company's ability to generate nearly $400M in gross profit without inventory costs suggests a scalable business model if clinical milestones are achieved.
Bear Case
The stock faces severe headwinds from a persistent net loss of $64.7M and negative operating cash flow of -$26.5M, indicating that current revenue is not yet covering operational burn. With total liabilities reaching $169.1M against only $3.6M in shareholders' equity, the company remains highly leveraged and vulnerable to capital market volatility.
About Oncology Institute, Inc.
Oncology Institute, Inc. (TOI) is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies to address unmet medical needs. The company primarily serves the oncology market with its pipeline assets aimed at treating various malignancies through innovative drug discovery and development programs. Key financial drivers include significant gross revenue of $393.4M in 2024, though the firm reports a net loss driven by high operational expenses.
Analysis
Management Discussion
Despite a robust 54% year-over-year revenue growth to $393.4M in 2024, the company continues to report substantial net losses, widening from a $83.1M loss in 2023 to a $64.7M loss last year. Operating expenses surged to $453.5M, significantly outpacing the gross profit of $393.4M, while financing activities saw cash outflows for share issuances and other obligations.
Industry Overview
The oncology sector is characterized by high barriers to entry, long development cycles, and significant regulatory hurdles for bringing new cancer therapies to market. Companies in this space often operate at a loss during clinical phases while relying on venture capital or public markets to fund R&D until product commercialization.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $252.5M | $324.2M | $393.4M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $252.5M | $324.2M | $393.4M |
| Operating Expenses | $334.4M | $401.3M | $453.5M |
| Operating Income | $-82.0M | $-77.0M | $-60.1M |
| G&A | $119.7M | $113.9M | $107.8M |
| Stock-Based Comp | $27.7M | $17.8M | $11.2M |
| D&A | $4.4M | $5.9M | $6.3M |
| Depreciation | $1.5M | $2.9M | $3.2M |
| Amortization | $2.9M | $3.0M | $3.1M |
| Other OpEx | $214.7M | $287.4M | $345.7M |
| Non-Operating Income | $81.9M | $-6.1M | $-4.5M |
| Pre-Tax Income | $-91.0K | $-83.1M | $-64.7M |
| Income Tax | $-243.0K | $-36.0K | $0 |
| Continuing Ops | $152.0K | $-83.1M | $-64.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $152.0K | $-83.1M | $-64.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $152.0K | $-83.1M | $-64.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $130.4M | $143.5M | $112.4M |
| Marketable Securities | $59.8M | $49.4M | $0 |
| Accounts Receivable | $39.8M | $42.4M | $48.3M |
| Inventory | $9.3M | $13.7M | $10.0M |
| Prepaid Expenses | — | $4.0M | $4.0M |
| Other Current Assets | $21.5M | $34.0M | $50.0M |
| Long-Term Assets | $131.2M | $65.7M | $60.3M |
| PP&E (Net) | $8.5M | $10.9M | $11.9M |
| Intangibles | $18.0M | $17.9M | $14.8M |
| Goodwill | $21.4M | $7.2M | $7.2M |
| Operating Leases | $24.5M | $29.2M | $25.8M |
| LT Investments | $58.4M | $0 | — |
| Other LT Assets | $477.0K | $561.0K | $589.0K |
| Total Assets | $261.7M | $209.2M | $172.7M |
| Current Liabilities | $29.7M | $34.8M | $52.2M |
| Accounts Payable | $9.4M | $14.4M | $24.3M |
| Current Debt | $0 | — | — |
| Current Leases | $5.5M | $6.4M | $6.8M |
| Deferred Revenue | $1.1M | $545.0K | $2.4M |
| Taxes Payable | $255.0K | $0 | — |
| Other Current Liab | $-1.1M | $-545.0K | $-2.4M |
| Long-Term Liabilities | $108.8M | $117.4M | $116.9M |
| Long-Term Debt | $80.6M | $86.8M | $93.1M |
| LT Operating Leases | $22.1M | $26.5M | $23.2M |
| Other LT Liab | $6.1M | $4.1M | $559.0K |
| Total Liabilities | $138.5M | $152.2M | $169.1M |
| Shareholders' Equity | $123.2M | $57.0M | $3.6M |
| Paid-In Capital | $186.2M | $204.2M | $215.4M |
| Retained Earnings | $-63.1M | $-146.2M | $-210.8M |
| Total L&E | $261.7M | $209.2M | $172.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $152.0K | $-83.1M | $-64.7M |
| Non-Cash Adjustments | $-70.5M | $38.5M | $21.5M |
| Working Capital Changes | $8.6M | $8.2M | $16.6M |
| Cash from Operations | $-61.8M | $-36.3M | $-26.5M |
| Capital Expenditures | $5.5M | $4.6M | $3.8M |
| Cash from Investing | $-131.6M | $62.6M | $46.2M |
| Debt Issuances | $110.0M | $0 | — |
| Debt Repayments | $0 | — | — |
| Share Buybacks | $9.0M | $1.0M | $0 |
| Cash from Financing | $92.2M | $-6.8M | $-3.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-101.2M | $19.5M | $16.2M |
| Beginning Cash | $115.2M | $14.0M | $33.5M |
| Ending Cash | $14.0M | $33.5M | $49.7M |
Frequently Asked Questions
How does Oncology Institute, Inc. make money?
The company's revenue is predominantly derived from its core biopharmaceutical product pipeline focused on oncology indications, supported by strategic collaborations that contribute to the reported gross profit without traditional inventory holding.
What are the main risks for TOI?
Significant financial risk is evident with a net loss of $64.7M in 2024 and an accumulated retained earnings deficit of over $210M. The company carries substantial long-term debt of $93.1M, creating liquidity pressure amidst negative operating cash flow. Additionally, the lack of commercial product sales indicates high dependency on future clinical trial success and potential partnership deals.
What is TOI's competitive advantage?
The firm leverages a proprietary drug discovery platform targeting difficult-to-treat cancer types, maintains strong cash reserves relative to current liabilities, and utilizes non-cash adjustments like share-based compensation to manage workforce growth.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.